Rochester,NY 8/19/2009 11:06:07 PM
Keryx Biopharmaceuticals Inc. KERX focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases.
Keryx Biopharmaceuticals, Inc.
Keryx Bio pharmaceuticals, Inc., a bio pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Its products under development include Zerenex, an oral iron-based compound is in Phase II clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease in the United States and Japan; and KRX-0401, an oral anti-cancer agent in Phase II clinical development that modulates Akt, and various other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. Keryx Biopharmaceuticals has strategic alliances with AEterna Zentaris Inc.; Panion & BF Biotech, Inc.; Japan Tobacco Inc.; and Torii Pharmaceutical Co., Ltd. for the manufacture and commercialization of its products. The company was formerly known as Lakaro Biopharmaceuticals, Inc. and changed its name to Keryx Biopharmaceuticals, Inc. in January 2000. Keryx Biopharmaceuticals, Inc. was founded in 1998 and is based in New York, New York.
StockEinstein.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
info@stockeinstein.com
stockeinstein.com
